WE INVEST IN LIFE

Ridgeline, a Versant Ventures Discovery Engine located in Switzerland, creates new biotech companies in partnership with entrepreneurs, industry and leading academics across Europe, US and RoW.

ABOUT US

Ridgeline, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry, and leading academics across Europe, US and RoW. In recent years, Ridgeline has assembled an international team of highly experienced drug discovery and industry professionals and built and operated multiple new successful companies; these companies have raised significant funds through Series B, IPO, Pharma Partnerships and an exit through a trade sale.

 
 
Logo_Versant_transparent.png
 

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.

VERSANT DISCOVERY ENGINES

Logo_Ridgeline_cmyk.png
Logo_Inception_rgb.png
 

Accessing the best science and innovation

RIDGELINE - A VERSANT VENTURES DISCOVERY ENGINE

DISCOVER

Ridgeline is rapidly developing the foundational science and technology of our new companies. Our goal is to grow these newcos into leading biotechs.

SOURCE

We partner with entrepreneurs and leading academics across Europe, US and RoW to access breakthrough transformational science that serves as the foundation of our company creation efforts.

DISCOVER

Together with our academic founders, our international team of accomplished industry R&D veterans drives research to create novel platforms and high-quality therapeutic candidates.

BUILD

Our international team has deep investment, research and operating experience that enables an efficient, hands-on approach to company building and value creation.

RIDGELINE BUILDS
COMPANIES

Ridgeline is a Versant Ventures Discovery Engine. Founded in 2017, Ridgeline has the mission to build new leading biotech companies, operate them, help them to grow and establish their own independent footprint. These include Black Diamond Therapeutics, Bright Peak Therapeutics, and Monte Rosa Therapeutics which operate fully independently. Several more recently founded companies, including Cimeio Therapeutics, Red Ridge Bio, and SixPeaks Bio are operating in collaboration with Ridgeline.

 

Novel platforms, breakthrough therapies

CAREER AT RIDGELINE

 

LEADERSHIP

Brad Bolzon, Ph.D.

Chairman and Managing Director at Versant Ventures

Ridgeline Discovery Board Member

Alexander Mayweg, Ph.D.

Managing Director at Versant Ventures

President and Ridgeline Discovery Board Member

Markus Enzelberger, Ph.D.

Partner at Versant Ventures

Ridgeline Discovery Board Member

Andrew Jefferson, BSc, MBA

Operating Partner at Versant Ventures

Chief Operating Officer at Ridgeline Discovery

Giorgio Ottaviani, Ph.D., DABT

Operating Partner at Versant Ventures

SVP of Preclinical Development at Ridgeline Discovery

 

TEAM

GET IN TOUCH

 

OFFICES

Ridgeline Discovery GmbH
c/o Versant Ventures
Aeschenvorstadt 36
CH 4051 Basel
Switzerland
info@ridgelinediscovery.com

 
 

OFFICES AND LABS

Ridgeline Discovery GmbH
Technologiepark
Hochbergerstrasse 60 F
CH 4057 Basel
Switzerland
info@ridgelinediscovery.com